Editing DNA could be genetic medicine breakthrough – SFGate

A new way to make powerful changes at will to the DNA of humans, other animals and plants, much like how a writer changes words in a story, could usher in a transformation in genetic medicine.

Scientists are not just excited about this recently discovered technique because it can snip and edit DNA with precision. It can also do the job more easily and cheaply than other gene-editing methods, making possible research that has historically been difficult, experts say.

Now some of the biologists who unlocked this tool, derived from the immune system of bacteria, are forming companies around it. Although this molecular system, known as Crispr, is not fully understood, researchers believe it can be harnessed to create therapies for intractable genetic diseases.

One of those scientists, UC Berkeley Professor Jennifer Doudna, was part of the team that in 2012 first demonstrated the technique. It is now employed by two companies she has co-founded: Caribou Biosciences in Berkeley, and Editas Medicine in Cambridge, Mass. The latter started last year with $43 million in venture capital. Another company, the aptly named Crispr Therapeutics in Switzerland, has $25 million in the bank, and other biotechnology companies are experimenting with the procedure.

"In principle, this is a technology that could enable correction of genetic mutations that would otherwise lead to disease," said Doudna, a professor of chemistry and biochemistry and molecular biology, in a telephone interview. She was among several experts who spoke at a UC Berkeley conference on the subject last month.

But because the method is in its infancy and has little precedent with the agencies that regulate medicines, it will almost certainly be a long time before a Crispr-based therapy makes it to market.

Its potential risks also concern some bioethicists.

"In the very worst case, technologies that can cause permanent inheritable changes in people bring you very close to the risk of modern eugenics," said Pete Shanks, a consultant who blogs about the topic for the Center for Genetics and Society, a bioethics watchdog organization in Berkeley. "Pretty much everyone agrees that we should avoid that. How we do that, comes the question."

The technique operates on the recent discovery that bacteria, like humans, have an immune system that remembers viruses that have attacked before. To protect themselves, bacteria chop up and incorporate short fragments of foreign invaders' genetic code so they know to destroy a virus should it strike again. It is their equivalent of developing vaccines.

Those new fragments in the bacterial genome add up to an "unusual structure," first reported in the late 1980s by scientists who called them "clustered regularly interspaced short palindromic repeats" - Crispr for short. But Crispr's role, to fight infections, wasn't confirmed until 2007.

Read this article:
Editing DNA could be genetic medicine breakthrough - SFGate

Genetic Medicine | Department of Pediatrics | University …

Leadership

Michael Bamshad, MD Professor Division Chief

The Division of Genetic Medicine is committed to providing an outstanding level of patient care, education and research. The faculty have diverse interests and are drawn from several disciplines including clinical genetics, molecular genetics, biochemical genetics, human embryology/teratology and neurology.

A large clinical program of medical genetics operates from Seattle Childrens Hospital staffed by faculty from the Division. These clinical activities concentrate on pediatric genetics but also encompass adult and fetal consultations. At Seattle Children's full IP consultations are available and general genetics clinics occur regularly. Consultative services are also provided to the University of Washington Medical Center and Swedish Hospital. In addition, a variety of interdisciplinary clinical services are provided at Childrens including cardiovascular genetics, skeletal dysplasia, neurofibromatosis, craniofacial genetics, gender disorders, neurogenetics and biochemical genetics as well as others. A very large regional genetics service sponsored by state Departments of Health are provided to multiple outreach clinical sites in both Alaska and Washington.

Our research holds the promise for both continued development of improved molecular diagnostic tools and successful treatment of inherited diseases. Research in the Division is highly patient-driven. It often begins with a physician identifying a particular patients problems and subsequently taking that problem into a laboratory setting for further analysis. The Division has a strong research focus with established research programs in medical genetics information systems, neurogenetic disorders, fetal alcohol syndrome, neuromuscular diseases, human teratology, population genetics/evolution and gene therapy.

The Division offers comprehensive training for medical students, residents, and postdoctoral fellows in any of the areas of our clinical and research programs relevant to medical genetics. Medical Genetics Training Website

Margaret L.P. Adam, MD Associate Professor mpa5@u.washington.edu

Visit link:

Genetic Medicine | Department of Pediatrics | University ...

Ohio State Gene Testing Could Unlock Key To Curing Cancer

COLUMBUS, Ohio - Cancer research goes beyond medicine at The Ohio State University's James Cancer Hospital.

Doctors conduct genetic testing at Ohio State, unraveling the genetic code of a specific cancer.

"The idea is can we identify what these cancers are, what's wrong with these cancers, and what's the right therapy for them?" said Dr. Sameek Roychowdhury.

Roychowdhury leads the precision cancer medicine program at the James. The focus of the program is just that precision.

Doctors have been analyzing tumors for years, but now it's so specific down to the genetic mutation.

"So if we saw 100 patients with breast cancer, we could literally find 100 different types of breast cancer," Roychowdhury said.

Getting to the genetic heart of the cancer, knowing what drives it and makes it grow and spread, is the key to finding the cancer, stopping it, and saving lives.

"It's going to be much more focusedon the exact gene that's disruptive," Roychowdhury said.

For example, Jared Gordon was diagnosed with stage four lung cancer at age 51.

The father of three was told that he had six months to live.

More:

Ohio State Gene Testing Could Unlock Key To Curing Cancer

Treatments improved through personalised medicine

The EU is investing in the development of personalised medicine, which allows doctors to offer preventative treatments for cancer and heart disease.

Most commonly used to treat cancer, personalised medicine can offer patients the best possible treatment by focusing on the individual genetic and biological make-up of their tumours. Thanks to advances in research, personalised medicine could be made available to more patients, and scientists are optimistic about its future.

If traditional treatments are ineffective, or the cancer is recurrent, patients can undergo tests to determine the specific molecular anomalies in their tumours, and how bestto block theirenzyme activity. Doctors can then target these anomalies, which may occur in multiple cancers, and are thus able to prescribe medication to treat several tumours simultaneously.

"Personalised medicine works by focusing on the genetic make-up of the tumour, rather than the patient," Agns Buzyn, president of the French National Cancer Institute (INCA), explained during a Medef Summer University workshop.

External factors such as environment and lifestyle are also taken into account, as they can influence a patient's illness andthe effectiveness of its treatment.

Heart disease risk-assessment

Personalised medicine can also be used to treat heart disease. Risk assessment can greatly improve the effectiveness of preventative treatment, and can enable doctors to intervene swiftly with effective measures before any problems arise.

By analysing the concentration of certain proteins in the blood, along with the patient's individual genetic data, it is possible to predict with relative accuracy whether the patient is at risk of developing heart disease in the future.

>> Read: New cardiovascular disease treatments urgently needed, experts say

Pharmaceutical companies take the strain

Read the original:

Treatments improved through personalised medicine

The genius of genomics

It is 14 years since Tony Blair and Bill Clinton invited the world's media to the White House for an announcement that would have seemed like science fiction just a few years earlier: the entire human genome - the genetic blueprint of human beings - had been mapped for the first time.

Looking somewhat awestruck, the prime minister and the president promised their press conference would pave the way for 'a new era of genetic medicine'.

This was not a hollow pledge, but genomics is only now beginning to fulfil its potential.

How can investors gain the diversification that is important in all facets of investing in biotechnology through genomics? Read more: Six stocks and funds to give investors exposure to genomics.

The two world leaders were right in their view that genomics would prove to be a disruptive technology (not that they would have used the term).

But just as it took the mass-produced Ford Model T to translate the invention of the automobile into a technology that changed the world, so the first map of the human genome was not quite the game changer Blair and Clinton anticipated.

'The real catalyst for the take-off of genomics has been the next-generation technology that has brought the cost of gene sequencing to an incredibly low level,' says Jung Ryu, a life sciences tools analyst at New York-based fund manager OrbiMed Advisors, which runs the Biotech Growth and Worldwide Healthcare investment trusts in the UK.

'That first human genome project was completed at a cost of $3 billion (1.8 billion) - by the end of this year, it will be possible to buy table-top gene sequencing equipment that can do the same job for less than $1,000.'

At that price, genomics research is possible in university labs all around the world, and projects of previously unimaginable ambition become cost-effective.

For example, in July in the UK, the National Health Service began awarding contracts for its 100,000 Genomes Project, an initiative to map the DNA of 100,000 Britons by 2017.

View original post here:

The genius of genomics

Proove Biosciences Will Be Exhibiting at the 21st Annual Napa Pain Conference

IRVINE, CA and ANNAPOLIS JUNCTION, MD (PRWEB) September 04, 2014

Proove Biosciences, the commercial and research leader in personalized medicine, will be attending the 21st Annual Napa Pain Conference, September 5th-7th, at the Meritage Conference Center. Proove will specifically be presenting research conducted through their proprietary PILL II Study.

The PILL II study examined the prevalence of genetic variations in a population of chronic pain patients who were taking prescription opioids. Proove researchers found that there is in fact a greater prevalence of these genetic variations in the study group vs. the control population.

The Napa Pain Conference is a leading CME pain management conference that traditionally presents new data and best practices in pain therapies. The conference is designed to provide significant educational opportunity to everyone, regardless of position, or role in the pain management and pain treatment industry.

Proove Biosciences genetic testing has allowed pain management physicians to better assess their patients needs by analyzing how they will react to specific treatments, and help physicians decide if there are better alternatives to consider, stated Brian Meshkin, CEO of Proove Biosciences.

The nationally acclaimed annual conference is the premier event for the study of pain diagnosis and treatment. Regarding opioids and addiction, the conference aims to provide an understanding of current medical treatment; review current processes for patients at risk for aberrant behaviors related to prescription drug abuse; discuss strategies to enhance safety; and increase awareness of best practices to help reduce and prevent opioid over-prescribing.

As the commercial leader in personalized pain medicine research and genetic testing, Proove Biosciences is committed to helping patients manage and treat their pain in the most efficient and safest way possible, stated Meshkin. This is only possible by truly understanding how the patient will react to treatment based off their individual genetic factors, and we are excited to share how Proove has been helping achieve this at the 21st Annual Napa Pain Conference.

About Proove Biosciences

Our mission is to change the future of medicine by providing proof to improve healthcare decisions. We envision a future when clinicians will know how patients are likely to respond to medications before writing a prescription. We believe such knowledge can be provided by genetic testing: Using a simple cheek swab, Proove performs proprietary genetic tests in its CLIA-certified laboratory. Healthcare providers use the results to evaluate how their patients will metabolize medications, and to screen for the likelihood of medication misuse.

Founded in 2009 with offices in Southern California and the Baltimore-Washington metropolitan area, Proove Biosciences is the leader in genetics-related personalized pain medicine research with hundreds of clinical research sites across the U.S. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

More:

Proove Biosciences Will Be Exhibiting at the 21st Annual Napa Pain Conference

Genetic 'hotspot' linked to endometrial cancer aggressiveness

PUBLIC RELEASE DATE:

3-Sep-2014

Contact: Ron Gilmore rlgilmore1@mdanderson.org 713-745-1898 University of Texas M. D. Anderson Cancer Center

Parents of twins often tell them apart through subtle differences such as facial expression, moles, voice tone and gait. Similarly, physicians treating women with endometrial cancer must be able to distinguish between different versions of this disease form that, on the surface, appear the same.

With endometrial cancer, the most common gynecological cancer in the western world and the fourth most prevalent in the U.S., it can literally be a matter of life and death. Mortality rates from this cancer have nearly tripled in the last 25 years and are thought to be attributed to the rising incidence of obesity.

Scientists at The University of Texas MD Anderson Cancer Center in Houston have identified genetic mutations in endometrioid endometrial carcinoma (EEC), the most common form of this cancer of the uterine lining. The mutations revealed a more lethal version of an EEC subtype previously thought to respond well to treatment. It's possible that by identifying these patients early on, oncologists can try more aggressive treatment approaches to increase the likelihood for a positive outcome.

"EEC is categorized into subtypes that help determine risk of recurrence and guide treatment," said Wei Zhang, Ph.D., professor of pathology at MD Anderson. "Most patients have Type I, which can be diagnosed early and generally has a good outcome with treatment."

Type I accounts for 70 to 80 percent of all EECs. Type II is more troublesome and is usually diagnosed late in the cancer's progression resulting in a poor prognosis. Zhang's team, however, identified a cluster of patients within Type I that appears to have a more virulent form of it previously not recognized. Zhang labeled this patient group as Cluster II.

"The patients were mostly younger and obese that's typical for Type I. What's unusual is for patients in this disease category to have decreased survival rates," said Zhang. "Molecular subtyping of EEC may help oncologists with diagnosis and prognosis within this unique subset."

Zhang believes that by being able to identify molecular "attributes," physicians can identify EEC patients at risk for this more lethal form of the disease.

Excerpt from:

Genetic 'hotspot' linked to endometrial cancer aggressiveness

ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application

WESTMINSTER, COLO.--(BUSINESS WIRE)--

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, today announced that the Companys Clinical Trial Application (CTA) for the GENETIC-AF clinical trial evaluating GencaroTM as a potential treatment for atrial fibrillation (AF) has been accepted by Health Canada. ARCA anticipates that clinical trial sites in Canada will be active in the fourth quarter of 2014.

Dr. Michael R. Bristow, President and CEO, ARCA biopharma, Inc. (Photo: Business Wire)

ARCA is evaluating Gencaro, a pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for AF in the Phase 2B/3 GENETIC-AF clinical trial, which is currently enrolling patients in the United States. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it potential to be the first genetically targeted therapy for the prevention of atrial fibrillation.

Dr. Michael R. Bristow, Founder and CEO of ARCA, commented, At ARCA, we believe a personalized medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. If the GENETIC-AF trial successfully confirms the atrial fibrillation data analysis from a prior Phase 3 clinical trial, Gencaro has the potential to be the first genetically targeted treatment for the prevention of this important cardiovascular disorder and provide a much needed treatment option for patients in an area of high unmet medical need.

About Atrial Fibrillation (AF)

Atrial fibrillation, the most common sustained cardiac arrhythmia, is considered an epidemic cardiovascular disease and a major public health burden. The estimated number of individuals with AF globally in 2010 was 33.5 million. According to the 2014 American Heart Association report on Heart Disease and Stroke Statistics, the estimated number of individuals with AF in the U.S. in 2010 ranged from 2.7million to 6.1million people. Hospitalization rates for AF increased by 23% among US adults from 2000 to 2010 and hospitalizations account for the majority of the economic cost burden associated with AF.

AF is a disorder in which the normally regular and coordinated contraction pattern of the hearts two small upper chambers (the atria) becomes irregular and uncoordinated. The irregular contraction pattern associated with AF causes blood to pool in the atria, predisposing the formation of clots potentially resulting in stroke. AF increases the risk of mortality and morbidity due to stroke, congestive heart failure and impaired quality of life. The approved therapies for the treatment or prevention AF have certain disadvantages in patients with heart failure and/or reduced left ventricular ejection fraction (HFREF) patients. These include toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contra indicated or have warnings in their prescribing information for such patients. The Company believes there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in HFREF patients.

GENETIC-AF Clinical Trial

GENETIC-AF is a Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing the safety and efficacy of Gencaro to Toprol-XL for prevention of symptomatic AF/atrial flutter in HFREF patients. ARCA plans to enroll only patients with the genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company initiated the trial as a Phase 2B trial in approximately 200 patients. The GENETIC-AF Data Safety Monitoring Board (DSMB) will analyze certain data from the Phase 2B portion of the trial and recommend, based on a comparison to the pre-trial statistical assumptions, whether the trial should proceed to Phase 3 and seek to enroll an additional 420 patients.

Continue reading here:

ARCA Biopharma Announces Health Canada Acceptance Of Genetic-AF Clinical Trial Application

Scientists devise a bar code for the bacteria that causes tuberculosis

PUBLIC RELEASE DATE:

1-Sep-2014

Contact: Jenny Orton press@lshtm.ac.uk 44-207-927-2802 London School of Hygiene & Tropical Medicine

Doctors and researchers will be able to easily identify different types of tuberculosis (TB) thanks to a new genetic barcode devised by scientists from the London School of Hygiene & Tropical Medicine.

The bacteria that cause the deadly respiratory disease have evolved into families of strains, or lineages, which may affect people differently.

To help identify the different origins and map how tuberculosis moves around the world, spreading from person to person through the air, the research team studied over 90,000 genetic mutations.

According to the study published in Nature Communications the researchers found that just 62 mutations are needed to code the global family of strains.

Dr Taane Clark, Reader in Genetic Epidemiology and Statistical Genomics at the London School of Hygiene & Tropical Medicine, who led the study, said: "There is increasing interest in new technologies that can assist those treating tuberculosis patients.

"This new barcode can be easily implemented and used to determine the strain-type that is a surrogate for virulence.

"We are making this information available to the doctors and scientists working with tuberculosis so that they can more easily know what strains they are dealing with."

See original here:

Scientists devise a bar code for the bacteria that causes tuberculosis

Pharmacogenetics advances personalized medicine

John Hwa is a professor of medicine and the director of cardiovascular pharmacogenetics at Yale School of Medicine. Along with Dartmouth genetics professor Jason H. Moore, Hwa recently coauthored an editorial in the journal Current Molecular Medicine. The article, titled Pharmacogenetics and Molecular Medicine: So Close and Yet So Far introduces a new review series of eight articles contributed by different researchers in the field of pharmacogenomics. The News sat down with Hwa and his colleague, Yale postdoctoral fellow Jeremiah Stitham, to understand the latest advances in the field.

Q. How would you define the fields of pharmacogenomics and personalized medicine to the general public? What are the basic underlying principles and ideas?

H. About 100,000 people die each year from adverse side effects to medications, and millions of others have some sort of harmful drug reaction. The idea of pharmacogenetics is to try and figure out, based on genetics, who is going to suffer problems and who will benefit the most from taking a particular drug. Though there are actually many definitions out there, the simplest definition is that it is a combination of pharmacology and genetics: pharmacogenetics. It is the use of genetic data to understand how a disease process is influenced by genetics, progresses as a result of genetics, and responds to drugs. In terms of the pharmacology, there are two main components, pharmacodynamics and pharmacokinetics: the former dealing with how genetics influences the drugs effect on the disease and the latter dealing with how genetics influences the metabolism of the drug.

Q. As your lab specializes in cardiovascular medicine, what has been the core focus of your research in particular?

H. Commonly used drugs that are taken for pain, arthritis and fever can have a profound effect on the cardiovascular system and one of the main reasons for this is because of problems with [the molecules] prostacyclin and thromboxane. This has become a very major concern in cardiovascular medicine and the clinical sciences. I am part of a large consortium based at the University of Pennsylvania that has come together to address this problem. We are trying to figure out who would benefit from these common drugs without adverse side effects and who should be careful about taking these medications: essentially the concept of personalized medicine. Currently, my lab is focusing our efforts on the diabetic population, because they are particularly at risk for cardiovascular diseases. We have all the tools now and are beginning to make sense of the data. There is not doubt that in the near future, we will be able to predict who is going to have adverse side effects as a result of a drug and who is going be fine and benefit from the treatment.

S. That is basically the third component of pharmacogenomics: the first two being how genetics affects drug response and drug metabolism and the final component being how it is going to affect people with adverse reactions.

Q. Which recent advances and discoveries have been game-changers? Have any new experimental techniques and technologies really impacted the way the scientific community studies this field?

H. One major advance has been the advent of genetic sequencing. Back in 2001, sequencing used to cost a fortune, but now prices have gotten significantly lower. Whole-genome sequencing now costs a few thousand dollars, and the price is going to drop even further. I have no doubt that one day everyone will sequence his or her genome.

In many ways, we are overwhelmed with data from all of these sources. The real question now is the hypothesis-generation procedure: how are you going to make sense of all of this information? Certainly with an area like pharmacogenetics, there is a vast amount of data that is being collected, at multiple levels, and ultimately it is going to be a cross-disciplinary collaboration between the basic scientists, the translational scientists, the clinicians, the bioinformaticists, and the outcomes specialists. It is going to be a collaboration that makes sense of the massive data sets that are being generated and applies this knowledge to clinical practice.

Q. In the title of your editorial, you state that the scientific community in this field is so close and yet so far. What are the major challenges currently faced by the fields of pharmacogenomics and personalized medicine?

The rest is here:

Pharmacogenetics advances personalized medicine

New child cancer specialist for Auckland

New child cancer specialist for Auckland

Paediatric oncologist, Dr Andrew Wood has returned to the University of Auckland to research the genetic mistakes driving childhood leukaemias.

Dr Wood graduated from the University of Aucklands School of Medicine, and trained as a paediatrician at Starship Childrens Hospital before going to the Childrens Hospital of Philadelphia as a Fulbright Scholar.

His research programme will study and model the genetic mistakes driving childhood leukaemias with the ultimate goal of finding Achilles heels that can be exploited to treat leukaemia in new ways.

After seven years at the United States number one ranked childrens hospital, the Childrens Hospital of Philadelphia (CHOP), he returned to New Zealand for family and friends and because there was a small but committed and capable team doing exciting work that he wanted to be part of.

Dr Wood specialises in the diagnosis and treatment of cancers in children and adolescents. Alongside treating patients at Starship Childrens Hospital he will lead a research team and collaborate internationally with the aim of making childhood cancer a stumbling block, not a road block.

He hopes his research will contribute to the long-term aim of improving survival rates for Kiwi kids with cancer and to cure more gently.

Cure Kids will be a major contributor to his programme of research that is based out of the University of Auckland. His repatriation to New Zealand is also supported by the Auckland Medical Research Foundation through a Goodfellow Repatriation Fellowship.

Cure Kids CEO Vicki Lee says Dr Woods appointment is a huge win for New Zealand child cancer research.

Cancer survival rates for children are a success story of modern medicine as diseases that were once death sentences now carry an average five-year survival rate of 80 percent.

See the article here:

New child cancer specialist for Auckland

Medicine's Next Big Mission: Understanding Wellness

The bioengineering pioneer Leroy Hood has seen vast changes in medicine over his decades in the biz, in part thanks to his own work on automated DNA sequencing. But he's not much for looking back he's too busy envisioning a future model of medicine. "Contemporary medicine is all about disease, and not about wellness," he says. Hood says the medical profession must learn to measure and maximize wellness, and he's happy to show the way.

At the annual meeting of the IEEE Engineering in Medicine and Biology Society, Hood presented his vision for "P4 medicine," which is predictive, preventive, personalized, and participatory. In a keynote speech, he described the 100K Wellness Project he launched this year as president of the Institute for Systems Biology. The ambitious study aims to enroll 100,000 participants and track their biometrics over 20 years (funding permitting). Hood wants to quantify wellness, and also to provide "actionable information" to the participants.

In March, the project enrolled 108 healthy people to take part in the pilot study. At the end of 2014 the project will scale up to 1000 participants, with the big steps to 10,000 and then 100,000 people expected in the next few years.

Each participant gets their whole genome sequenced at enrollment, and then every three months provides samples of blood, saliva, urine, and stool for analysis. Users also submit data from self-trackers like the Fitbit activity tracker and Omron blood pressure monitor.All that information is integrated to create a dynamic picture of the person's biological state. As the years go by, "patients will either stay well or transition into disease," Hood says. The collected data will not only define the biological parameters of wellness when a participant is diagnosed with a disease, researchers can go back through that patient's data to identify early warning signs.

In a conversation with Spectrum, Hood described the study's first results. All 108 people were found to have some actionable possibility, and received counseling from the project's health coaches. For example, 85 people had low levels of vitamin D. The researchers then checked those people's genomes, and identified some people with a genetic variation that makes it difficult for their bodies to absorb vitamin D. The health coaches could therefore tell each of those 85 people how much vitamin D they needed to take to bring up their levels.

One of the participants received even more critical information. Blood testing revealed that his iron levels were very high, and the health coaches advised him to go to a doctor. It turns out he had a dangerous genetic condition called hemochromatosis that damages the organs and eventually leads to heart attack, but that can be managed by bringing down iron levels. "So instead of having an individual who is sick for the last 20 years of his life, we have a healthy individual," Hood says. That substitution is not just a good health outcome, it's also a significant cost saving for the health care system.

Hood thinks his study of wellness is of such national importance that he's considering pitching it to Congress as "a second Human Genome Project." He would argue that the study would bring about great innovations and cost savings in health care, and would let the United States lead a revolution in medicine. "I think the arguments are actually better for this than they were for the genome project," Hood says.

Advertisement

IEEE Spectrums general technology blog, featuring news, analysis, and opinions about engineering, consumer electronics, and technology and society, from the editorial staff and freelance contributors.

Sign up for the Tech Alert newsletter and receive ground-breaking technology and science news from IEEE Spectrum every Thursday.

Read more:

Medicine's Next Big Mission: Understanding Wellness

Tute Genomics and Patients Know Best Partner to Bring Precision Medicine' a Step Closer

Provo, Utah (PRWEB) August 27, 2014

Tute Genomics is today teaming up with UK-based Patients Know Best the worlds first fully patient controlled medical records system to make precision medicine a reality to patients across the globe.

Operating a cloud-based software platform, Tute Genomics specializes in genome analysis, creating meaningful reports of an individuals full genomic profile that doctors and patients alike can interpret and use to gain meaningful and actionable insights about their health.

The partnership between the two companies will mean that for the first time a patients full genetic profile and one that is easy to work with and understand can be stored within their healthcare record. For the patient, this will ultimately result in receiving healthcare services that are precision-made for their particular condition based on their individual genome sequence.

Dr Reid Robison, CEO of Tute Genomics said,Were enthusiastic about this new partnership with Patients Know Best because we share the same philosophies about pushing genomic medicine forward. Patients Know Best believes in creating a system that will reduce errors and raise quality of healthcare and that is the purpose of the Tute genomics platform; enabling precision medicine. Tute Genomics is working hard to make genomics more accessible to healthcare, research and even consumers, in order to advance individualized, genome-guided medicine.

Over the past few years genomic sequencing 'mapping out' a persons full DNA has become far cheaper and therefore far more feasible. Full genome sequencing involves testing 25,000 separate genomes and 'reading off' 6 billion letters (3 billion base pairs) in any given human genome. Approximately 10 years ago it cost over $100 million to sequence a persons full genome. Today, the cost stands at around $1000.

Dr Mohammad Al-Ubaydli, CEO of Patients Know Best said, When doctors know an individuals genomic profile they can design plans that exactly treat their condition. For example, gene tests can predict whether or not a patient with breast cancer will benefit from a certain type of chemotherapy, or a patient with an infection can safely receive powerful antibiotics. We believe that before long, everyone will get his or her genome sequenced. Tute is providing the most powerful genetic analysis in the hands of patients.

About Patients Know Best Patients Know Best is the worlds first patient-controlled medical records system. It is a fully secure online tool which enables patients to better organise, manage and control their own health care provision it also saves the time of physicians through allowing secure, online consultations. Founded by Dr. Mohammad Al-Ubaydli, a physician, programmer and expert in IT in healthcare, Patients Know Best has won social enterprise awards for its focus on patient care. Patients Know Bests first customers include Great Ormond Street Hospital, St Marks Hospital and NHS South Devon. Patients Know Best integrates fully into the NHS secure network and is available for use by any patient with any clinician anywhere in the world. It is now used by over 30 hospitals in the UK, USA, Holland, Ireland, Kuwait, Australia and Hong Kong. Patients Know Best complies fully with UK NHS information governance requirements as well as the EU data protection act and US HIPAA legislation for dealing with medical data. http://www.patientsknowbest.com

About Tute Genomics Tute Genomics is a USA-based company developing innovative cloud-based solutions to accelerate genetic discovery and enable precision medicine. Tute created a clinical genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Given sequencing data on a genome or a panel of genes, Tute can return over 125 annotations on variants and genes, perform family-based, case/control or tumor sample analyses to identify causal disease genes, and generate clinical reports for clinicians to focus on clinically relevant and actionable findings. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation & interpretation technology with over 800 scientific publications. The genome revolution is here, and Tute envisions a future where clinical reports on genomes are interactive and integrated into medical records, and aims to be the 'dropbox for genomes' for clinicians and patients alike. To learn more please visit http://www.tutegenomics.com.

Contact: Chris Smith, Swarm Communications +44 (0) 7989 321 743 chris(at)swarmcommunications(dot)co.uk

View original post here:

Tute Genomics and Patients Know Best Partner to Bring Precision Medicine' a Step Closer

Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer

Illumina Illumina, the leading maker of DNA sequencing equipment, is partnering with Sanofi Sanofi, AstraZeneca AstraZeneca, and Johnson & Johnson Johnson & Johnson to create a test for more mutations in dozens of genes that will be used first in clinical trials and, eventually, to help decide which patient should get which marketed drug.

The tool is necessary because new cancer drugs like Roches Zelboraf and Astras Iressa work only against cells that became cancerous because of particular genetic mutations. Detecting these mutations will allow doctors to pick drugs and cocktails of drugs aimed at the molecular machinery of a particular tumor. For instance, some research has shown that if a colorectal cancer tumor has a particular mutation, it might respond to the combination of a drug like Zelboraf and one like Iressa.

Illumina CEO Jay Flatley leads the innovative company.

Earlier this year, I met with Richard Klausner, Illuminas chief medical officer and the former director of the National Cancer Institute. He told me that he had been visiting large pharmaceutical companies with plans to develop a kind of master test. The idea is that companies would tell Illumina what cancer genes they are developing drugs targeted against. Then, using this information from all of these companies, it could create a genetic test that runs on its DNA sequencing machines that all companies could use in clinical trials, so that instead of developing tests one by one there would be a single test.

The goal is that everyone will use a universal panel, Klausner told me. This appears to be a step in that direction. Illumina says in its press release that the new test will look at at least 125 knownabout 60 or 70 cancer-causing genes. The test will run on MiSeqDx, the only next-generation DNA sequencing machine approved by the Food and Drug Administration. That could put Illumina in partial competition with some of its customers, like Foundation Medicine, which offers DNA sequencing tests for choosing cancer drugs, although Klausner told me he foresees technologies like Foundations being used for more complex analyses or more complicated cases. I think there is plenty of room, Klausner says.

The transition to patient-centered companion therapeutics marks a new era for oncology, and we are pleased to see pharmaceutical companies working with Illumina on a universal platform to bring life- saving treatments through their development pipelines, said Ellen V. Sigal, Ph.D., Chair and Founder of Friends of Cancer Research, in a prepared statement issued by Illumina. This is the type of collaboration that will make real progress for patients.

Klausner told me in an interview last night that the partnerships with the drug giants will be three-pronged: a technical partnership for creating the tests; a regulatory partnership for dealing with the FDA and other regulators; and a commercial partnership, in which Illumina guarantees it will make the tests available where companies sell their drugs.

As a regulatory framework, this could be disruptive. The FDA currently talks about companion diagnostics, that is, diagnostic tests that are paired with drugs. But Klausner says he is thinking in terms of companion therapeutics: in other words, all the drugs are paired with the same test. Its a big change, he says. The FDA is totally embracing it.

For more on Illumina, its history, and the potential of DNA sequencing, read my profile of the company and its CEO, Jay Flatley, in the current issue of Forbes.

Here is the original post:

Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer

Angiocrine Bioscience Licenses New Stem Cell Technology from Weill Cornell Medical College

NEW YORK--(BUSINESS WIRE)--Angiocrine Bioscience, Inc. announced today that it has licensed the rights to a new technology developed by a team of researchers at the Ansary Stem Cell Institute at Weill Cornell Medical College. The team was led by Dr. Shahin Rafii, director of the Ansary Stem Cell Institute, professor of medicine, genetic medicine and reproductive medicine, and a founder of Angiocrine Bioscience. This scientific advance, reported in the July 2 issue of Nature, could potentially lead to therapies for patients with blood disorders from their own cells.

This technology provides a means of converting a patients own vascular cells, known as endothelial cells, directly into blood stem cells. The endothelial cells are acquiredfrom a biopsied piece of skin and are then educated on a bed of VeraVecTM cells (proprietary to Angiocrine Bioscience) to form multipotent blood cells that are capable of producing red cells that carry oxygen, white cells that provide immunity, and platelets to prevent bleeding. This approach could potentially provide an abundant and safe source of new blood stem cells capable of treating a variety of diseases without the risk of graft versus host disease, a serious, life-threatening complication often associated with stem cell transplants derived from a donor.

"We hope that our method will offer the first safe technology to treat a wide spectrum of serious disorders. The VeraVecTM cells form a nurturing niche for the survival and growth of the reprogrammed blood cells, similar to what happens developmentally during blood production. A particularly important aspect of this study was that the reprogrammed cells engrafted in the bone marrow when implanted into rodents and morphed into the various types of blood cells, said Dr. Rafii.

This technology nicely complements our efforts in applying our VeraVecTM platform to the expansion of umbilical cord blood stem cells, another approach toward making stem cell transplant safer and more broadly available to patients in need, added Geoff Davis, Angiocrines CEO.

About Angioicrine Bioscience, Inc.

Angiocrine Bioscience is a privately held biotech company focused on applying vascular biology to new therapeutic applications. Angiocrines VeraVecTM technology platform is based on endothelial cells that have been genetically modified such that they can be rapidly and durably expanded in culture. Because these cells secrete and display factors essential for stem cell growth and proliferation, they can be used to support cell-based therapies, stem cell transplant, and regenerative medicine applications. VeraVecTM products are currently marketed for research-use only purposes to academic laboratories, medical research institutes, and pharmaceutical and biotechnology companies.

Read more from the original source:
Angiocrine Bioscience Licenses New Stem Cell Technology from Weill Cornell Medical College

Genetics in Medicine Journal Receives Record High Impact Factor of 6.435 for 2013

BETHESDA, Md., Aug. 5, 2014 /PRNewswire-USNewswire/ --The American College of Medical Genetics and Genomics (ACMG) announced that the Thomson Reuters Impact Factor Journal Citation Reports has just increased the impact factor of the ACMG's peer-reviewed medical genetics and genomics journal, Genetics in Medicine (GIM) to 6.435 in 2013 up from 5.56 in 2012.GIM is currently ranked 17th of 164 titles in Genetics & Heredity category and in the very top echelon of genetic journals that have a primarily clinical focus.A journal's Impact Factor is an objective measure of the world's leading journals based on articles' cited references and is oft considered a measure of a journal's overall successful performance and relevance to its field.

"We're delighted with our impact factor having jumped once again. We are gratified that Genetics in Medicine has gained further prominence and we hope it reflects progress towards our goal of being the 'go to' journal for all those involved in any facet of clinical genetics and genomics," said GIM's Editor-in-Chief Jim Evans, MD, PhD, FACMG.

"The Impact Factor is just one measure of a journal's value but this gratifying rise in GIM's impact is a testament to our editorial board members, who carefully consider each submission to find those of greatest importance to our field. The rising impact factor of Genetics in Medicine is also a pleasing reflection of the growing importance of genetics and genomics in patient care more broadly," added Evans.

Gail Herman, MD, PhD, FACMG and president of the ACMG said, "This is a very rewarding and dramatic rise in our Impact Factor. As a leading academic journal and as the official journal of the ACMG, we know that GIM will continue to play a critical role in setting the standard for the practice of medicine whenever it involves genetic and genomic issues."

Genetics in Medicine is published by Nature Publishing Group (www.nature.com/gim)

The journal, published since 1998, is supported by an expert Board of Editors representing all facets of genetic medicine including such specialties as biochemical genetics, cytogenetics and pharmacogenetics.

About the ACMG and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (www.acmg.net) advances the practice of medical genetics and genomics by providing education, resources and a voice for more than 1700 biochemical, clinical, cytogenetic, medical and molecular geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG is the only nationally recognized medical organization dedicated to improving health through the practice of medical genetics and genomics. The College's mission includes the following goals: 1) to define and promote excellence in the practice of medical genetics and genomics and to facilitate the integration of new research discoveries into medical practice; 2) to provide medical genetics and genomics education to fellow professionals, other healthcare providers, and the public; 3) to improve access to medical genetics and genomics services and to promote their integration into all of medicine; and 4) to serve as advocates for providers of medical genetics and genomics services and their patients. Genetics in Medicine, published monthly, is the official ACMG peer-reviewed journal. ACMG's website (www.acmg.net) offers a variety of resources including Policy Statements, Practice Guidelines, Educational Resources, and a Find a Geneticist tool. The educational and public health programs of the American College of Medical Genetics are dependent upon charitable gifts from corporations, foundations, and individuals through the ACMG Foundation for Genetic and Genomic Medicine (www.acmgfoundation.org.)

SOURCE American College of Medical Genetics and Genomics

RELATED LINKS http://www.acmg.net

See more here:
Genetics in Medicine Journal Receives Record High Impact Factor of 6.435 for 2013

Rady gives $120M for genetic medicine institute

SAN DIEGO Rady Childrens Hospital announced Monday a $120 million gift frombenefactor Ernest Rady and his family to establish the Rady Pediatric Genomics and Systems Medicine Institute.

Ernest Rady

As we move into an exciting new era of medicine, it is our responsibility to encourage the ambitious research and innovation that will accelerate the process by which discoveries are made and translated into cures, Rady said.

Hospital officials said that discoveries in genomics and emerging personalized medicines hold unprecedented promises, but breakthroughs are required to translate the advances into cures and treatments.

The gift will enable Rady Childrens to keep pace with new technology and stay on the cutting edge of genomics and systems medicine, according to the hospital.

Rady Childrens plans to spend $40 million of its own money on the project, which will be housed on the Rady Childrens campus and a separate location in the Torrey Pines life sciences hub.

The institute will work closely with UC San Diego and establish relationships with other academic and research institutions, companies involved in genomics research and other childrens hospitals to advance the mission of the institute, said David Hale, chairman of the board.

Rady, who founded the real estate, investment and financial firm American Assets Inc., gave the pediatric hospital $60 million in 2006.

Follow this link:
Rady gives $120M for genetic medicine institute

USC Institute of Genetic Medicine Exhibition “Molecular and Social Systems” – Video


USC Institute of Genetic Medicine Exhibition "Molecular and Social Systems"
Molecular and Social Systems: Learning through Creative Exploration The University of Southern California University of Southern California Keck School of Me...

By: Professor Marcela Oliva

Read this article:
USC Institute of Genetic Medicine Exhibition "Molecular and Social Systems" - Video

UCLA Awarded $7 Million to Unravel Mystery Genetic Diseases

Contact Information

Available for logged-in reporters only

Newswise The David Geffen School of Medicine at UCLA is one of six institutions nationwide chosen by the National Institutes of Health to join their effort in tackling the most difficult-to-solve medical cases and develop ways to diagnose rare genetic disorders. Part of a $120 million initiative called the Undiagnosed Diseases Network, the four-year $7.2 million UCLA grant will enable comprehensive bedside to bench clinical research to support physicians efforts to give long-sought answers to patients who have been living with mystery diseases.

Undiagnosed diseases take a huge toll on patients, their families and the health care system, said Dr. Katrina Dipple, a co-principal investigator of the grant with Drs. Stanley Nelson, Christina Palmer and Eric Vilain. This funding will accelerate and expand our clinical genomics program, enabling us to quickly give patients a firm diagnosis and clarify the best way to treat them.

Despite extensive clinical testing by skilled physicians, some diseases remain unrecognized because they are extremely rare, underreported or atypical forms of more common diseases. An interdisciplinary team of geneticists at each of the network sites will examine and study patients with prolonged undiagnosed diseases.

A vast number of children and adults suffer from severe, often fatal undiagnosed disorders, explained Vilain. This program will enable us to discover new genes causing ultra-rare medical conditions and to identify environmental factors that lead to disease or interact with genes to cause disease.

Patients will undergo an intensive week-long clinical assessment that includes a clinical evaluation, consultations with specialists and medical tests, including genome sequencing to identify genetic mutations. The team will also evaluate the impact of genetic counseling and genomic test results on patients and families to develop best practices for conveying this information.

The Undiagnosed Diseases Network capitalizes upon the strengths of UCLAs genetic medicine program, particularly its Clinical Genomics Center, which utilizes powerful sequencing technology to diagnose rare genetic disorders. Using a simple blood sample from a patient and both parents, the test simultaneously searches 37 million base pairs in 20,000 genes to pinpoint the single DNA change responsible for causing a patients disease. To date, a specific genetic explanation has been identified in a quarter of the cases evaluated with this test, as well as a number of novel disease-causing genes.

UCLA is the only facility in the western U.S. and one of only three nationwide that has a laboratory that can perform genomic sequence directly usable for patient care. The UCLA Medical Genetics Clinic cares for more than 750 new patients per year, and offers comprehensive pre- and post-test genetic counseling.

All patient studies will take place on the university campus at the Clinical Translational Research Center of the Clinical and Translational Science Institute. Network investigators will share genomic and clinical data gleaned from patients with their research colleagues nationwide to enhance understanding of rare and unknown diseases.

The rest is here:
UCLA Awarded $7 Million to Unravel Mystery Genetic Diseases

Mitochondrial Mutation Linked to Congenital Myasthenic Syndrome

Although significant progress has been made over the last 25 years to identify genetic abnormalities associated with congenital myasthenic syndromes (CMS), many patients remain genetically undiagnosed. A report in the inaugural issue of the Journal of Neuromuscular Diseases identifies a gene defect in mitochondria, specifically the citrate carrier SLC25A1, that may underlie deficits in neuromuscular transmission seen in two siblings.

"While mitochondrial gene defects can cause a myriad of neurological disorders including myopathies and neuropathies, these have not been specifically implicated in defects of the neuromuscular junction," says Hanns Lochmller, MD, Professor of Experimental Myology, Institute of Genetic Medicine, MRC Centre for Neuromuscular Diseases, Newcastle University, Newcastle upon Tyne, UK.

Of the 19 genes that have been implicated in CMS, most express proteins involved in neuromuscular synapse development and function. These mutations usually involve post-synaptic proteins. The current study shifts the area of impairment to the presynaptic region.

Investigators conducted genomic analyses of two patients who are brother and sister. The pair was born to healthy parents who were first cousins. "The family history was highly suggestive of autosomal recessive inheritance," notes Dr. Lochmller. Since childhood, the 33-year-old brother had displayed some speech and motor problems that worsened with exercise and improved with rest. He had mild bilateral ptosis (drooping of the eyelid), speech difficulties, and mild learning disabilities. His 19-year-old sister showed delayed development including recurrent falls, fatigable limb weakness, intermittent double vision, and some drooping of facial muscles.

The investigators performed homozygosity mapping and whole exome sequencing to determine the underlying genetic cause of the siblings' condition and successfully identified a homozygous mutation in the SLC25A1 gene. SLC25A1 is a mitochondrial citrate carrier believed to be a key component in many important biological processes, such as fatty acid and sterol biosynthesis, gluconeogenesis, glycolysis, maintenance of chromosome integrity, and regulation of autophagy.

Using electrophysiologic techniques, researchers were able to show clear abnormalities in the neuromuscular junctions of the patients, as evidenced by increased jitter or jitter with blocking of muscle fibers.

Researchers also found evidence that SLC25A1 may be required for normal neuromuscular junction formation by looking at the effects of reduced expression of SLC25A1 in zebrafish embryos. Anatomically, while the muscle fibers appeared normal, presynaptic motor axon terminals were shortened and grew erratically, with no evidence of complete synapse formation. They also saw structural changes in the brain and heart, which mirrored abnormalities seen in humans.

"It is still not clear how deficits in a mitochondrial citrate carrier result in neuromuscular junction defect," comments Dr. Lochmller. However, while mutations in SLC25A1 may prove to only be a rare cause of CMS, he and his co-investigators advise clinicians that should a patient show fatigable weakness, it may be appropriate to test for SLC25A1 mutations and consider screening for cardiac and metabolic defects should these mutations be found.

"We aimed to identify the underlying molecular defect in this family ever since we met them first in clinic more than 20 years ago," adds co-investigator Kate Bushby, MD, Professor of Neuromuscular Genetics, Institute of Genetic Medicine, MRC Centre for Neuromuscular Diseases, Newcastle University. "We are pleased that latest sequencing technology has resolved this long-standing diagnostic puzzle, which helps us in counseling and treating them more effectively."

Congenital myasthenic syndromes (CMS) are a group of inherited neuromuscular disorders characterized by muscle weakness (myasthenia). Typical symptoms include weakness of muscles controlling limbs, as well those involved with control of the eyes, respiration, and movements of the face, head, and neck (due to involvement of the corticobulbar tract). The symptoms are fatigable, meaning that they worsen with repetition, and severity of the deficits can range from mild to severe.

Read this article:
Mitochondrial Mutation Linked to Congenital Myasthenic Syndrome